Cerity Partners
NRIX icon

Cerity Partners’s Nurix Therapeutics NRIX Stock Holding History

Cerity Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Buy
17,254
+3,926
+29% +$66.9K ﹤0.01% 2549
2026
Q1 		$207K Buy
+13,328
New +$221K ﹤0.01% 2866
2025
Q1 		– Sell
-10,743
Closed -$241K – 2572
2024
Q4 		$241K Buy
10,743
+1
+0% +$23 ﹤0.01% 2143
2024
Q3 		$241K Buy
+10,742
New +$243K ﹤0.01% 2208
2024
Q2 		– Sell
-10,738
Closed -$158K – 2345
2024
Q1 		$158K Buy
+10,738
New +$115K ﹤0.01% 2153

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners's NRIX Position: Q2 2026 in Review

Cerity Partners increased its Nurix Therapeutics (NRIX) stake by 29% in Q2 2026, buying an estimated $66.9K and bringing the position to 17,254 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Cerity Partners first reported a position in NRIX in Q1 2024 and has held it in 5 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Cerity Partners held 17,254 shares of Nurix Therapeutics worth $419K as of Q2 2026.
  • Cerity Partners bought 3,926 Nurix Therapeutics shares in Q2 2026, an estimated $66.9K.
  • Nurix Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2549 holding.
  • Cerity Partners first reported a position in Nurix Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.